ZLAB vs. ASND, CERE, ITCI, JAZZ, BPMC, VKTX, IONS, CYTK, SMMT, and OGN
Should you be buying Zai Lab stock or one of its competitors? The main competitors of Zai Lab include Ascendis Pharma A/S (ASND), Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), Viking Therapeutics (VKTX), Ionis Pharmaceuticals (IONS), Cytokinetics (CYTK), Summit Therapeutics (SMMT), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical preparations" industry.
Ascendis Pharma A/S (NASDAQ:ASND) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking.
Zai Lab has a net margin of -116.45% compared to Zai Lab's net margin of -152.68%. Ascendis Pharma A/S's return on equity of -40.21% beat Zai Lab's return on equity.
Ascendis Pharma A/S has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.
41.7% of Zai Lab shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 5.2% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Zai Lab. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 5 mentions for Zai Lab. Zai Lab's average media sentiment score of 1.15 beat Ascendis Pharma A/S's score of 1.09 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.
Ascendis Pharma A/S presently has a consensus target price of $179.44, suggesting a potential upside of 32.43%. Zai Lab has a consensus target price of $64.22, suggesting a potential upside of 223.22%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Zai Lab is more favorable than Ascendis Pharma A/S.
Zai Lab has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.
Ascendis Pharma A/S received 191 more outperform votes than Zai Lab when rated by MarketBeat users. Likewise, 65.45% of users gave Ascendis Pharma A/S an outperform vote while only 63.58% of users gave Zai Lab an outperform vote.
Summary
Zai Lab beats Ascendis Pharma A/S on 10 of the 18 factors compared between the two stocks.
Get Zai Lab News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
